Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies

Jinho Lee, Gary K. Geiss, Gokhan Demirkan, Christopher P. Vellano, Brian Filanoski, Yiling Lu, Zhenlin Ju, Shuangxing Yu, Huifang Guo, Lisa Y. Bogatzki, Warren Carter, Rhonda K. Meredith, Savitri Krishnamurthy, Zhiyong Ding, Joseph M. Beechem, Gordon Mills

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Molecular analysis of tumors forms the basis for personalized cancer medicine and increasingly guides patient selection for targeted therapy. Future opportunities for personalized medicine are highlighted by the measurement of protein expression levels via immunohistochemistry, protein arrays, and other approaches; however, sample type, sample quantity, batch effects, and “time to result” are limiting factors for clinical application. Here, we present a development pipeline for a novel multiplexed DNA-labeled antibody platform which digitally quantifies protein expression from lysate samples. We implemented a rigorous validation process for each antibody and show that the platform is amenable to multiple protocols covering nitrocellulose and plate-based methods. Results are highly reproducible across technical and biological replicates, and there are no observed “batch effects” which are common for most multiplex molecular assays. Tests from basal and perturbed cancer cell lines indicate that this platform is comparable to orthogonal proteomic assays such as Reverse-Phase Protein Array, and applicable to measuring the pharmacodynamic effects of clinically-relevant cancer therapeutics. Furthermore, we demonstrate the potential clinical utility of the platform with protein profiling from breast cancer patient samples to identify molecular subtypes. Together, these findings highlight the potential of this platform for enhancing our understanding of cancer biology in a clinical translation setting.

Original languageEnglish (US)
Pages (from-to)1245-1258
Number of pages14
JournalMolecular and Cellular Proteomics
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2018
Externally publishedYes

Fingerprint

Proteomics
Antibodies
DNA
Protein Array Analysis
Precision Medicine
Neoplasms
Proteins
Medicine
Assays
Pharmacodynamics
Collodion
Patient Selection
Tumors
Pipelines
Immunohistochemistry
Cells
Breast Neoplasms
Cell Line
Therapeutics

ASJC Scopus subject areas

  • Analytical Chemistry
  • Biochemistry
  • Molecular Biology

Cite this

Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. / Lee, Jinho; Geiss, Gary K.; Demirkan, Gokhan; Vellano, Christopher P.; Filanoski, Brian; Lu, Yiling; Ju, Zhenlin; Yu, Shuangxing; Guo, Huifang; Bogatzki, Lisa Y.; Carter, Warren; Meredith, Rhonda K.; Krishnamurthy, Savitri; Ding, Zhiyong; Beechem, Joseph M.; Mills, Gordon.

In: Molecular and Cellular Proteomics, Vol. 17, No. 6, 01.06.2018, p. 1245-1258.

Research output: Contribution to journalArticle

Lee, J, Geiss, GK, Demirkan, G, Vellano, CP, Filanoski, B, Lu, Y, Ju, Z, Yu, S, Guo, H, Bogatzki, LY, Carter, W, Meredith, RK, Krishnamurthy, S, Ding, Z, Beechem, JM & Mills, G 2018, 'Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies', Molecular and Cellular Proteomics, vol. 17, no. 6, pp. 1245-1258. https://doi.org/10.1074/mcp.RA117.000291
Lee, Jinho ; Geiss, Gary K. ; Demirkan, Gokhan ; Vellano, Christopher P. ; Filanoski, Brian ; Lu, Yiling ; Ju, Zhenlin ; Yu, Shuangxing ; Guo, Huifang ; Bogatzki, Lisa Y. ; Carter, Warren ; Meredith, Rhonda K. ; Krishnamurthy, Savitri ; Ding, Zhiyong ; Beechem, Joseph M. ; Mills, Gordon. / Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies. In: Molecular and Cellular Proteomics. 2018 ; Vol. 17, No. 6. pp. 1245-1258.
@article{fed2f07b89134903ab9107a4238caede,
title = "Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies",
abstract = "Molecular analysis of tumors forms the basis for personalized cancer medicine and increasingly guides patient selection for targeted therapy. Future opportunities for personalized medicine are highlighted by the measurement of protein expression levels via immunohistochemistry, protein arrays, and other approaches; however, sample type, sample quantity, batch effects, and “time to result” are limiting factors for clinical application. Here, we present a development pipeline for a novel multiplexed DNA-labeled antibody platform which digitally quantifies protein expression from lysate samples. We implemented a rigorous validation process for each antibody and show that the platform is amenable to multiple protocols covering nitrocellulose and plate-based methods. Results are highly reproducible across technical and biological replicates, and there are no observed “batch effects” which are common for most multiplex molecular assays. Tests from basal and perturbed cancer cell lines indicate that this platform is comparable to orthogonal proteomic assays such as Reverse-Phase Protein Array, and applicable to measuring the pharmacodynamic effects of clinically-relevant cancer therapeutics. Furthermore, we demonstrate the potential clinical utility of the platform with protein profiling from breast cancer patient samples to identify molecular subtypes. Together, these findings highlight the potential of this platform for enhancing our understanding of cancer biology in a clinical translation setting.",
author = "Jinho Lee and Geiss, {Gary K.} and Gokhan Demirkan and Vellano, {Christopher P.} and Brian Filanoski and Yiling Lu and Zhenlin Ju and Shuangxing Yu and Huifang Guo and Bogatzki, {Lisa Y.} and Warren Carter and Meredith, {Rhonda K.} and Savitri Krishnamurthy and Zhiyong Ding and Beechem, {Joseph M.} and Gordon Mills",
year = "2018",
month = "6",
day = "1",
doi = "10.1074/mcp.RA117.000291",
language = "English (US)",
volume = "17",
pages = "1245--1258",
journal = "Molecular and Cellular Proteomics",
issn = "1535-9476",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "6",

}

TY - JOUR

T1 - Implementation of a Multiplex and Quantitative Proteomics Platform for Assessing Protein Lysates Using DNA-Barcoded Antibodies

AU - Lee, Jinho

AU - Geiss, Gary K.

AU - Demirkan, Gokhan

AU - Vellano, Christopher P.

AU - Filanoski, Brian

AU - Lu, Yiling

AU - Ju, Zhenlin

AU - Yu, Shuangxing

AU - Guo, Huifang

AU - Bogatzki, Lisa Y.

AU - Carter, Warren

AU - Meredith, Rhonda K.

AU - Krishnamurthy, Savitri

AU - Ding, Zhiyong

AU - Beechem, Joseph M.

AU - Mills, Gordon

PY - 2018/6/1

Y1 - 2018/6/1

N2 - Molecular analysis of tumors forms the basis for personalized cancer medicine and increasingly guides patient selection for targeted therapy. Future opportunities for personalized medicine are highlighted by the measurement of protein expression levels via immunohistochemistry, protein arrays, and other approaches; however, sample type, sample quantity, batch effects, and “time to result” are limiting factors for clinical application. Here, we present a development pipeline for a novel multiplexed DNA-labeled antibody platform which digitally quantifies protein expression from lysate samples. We implemented a rigorous validation process for each antibody and show that the platform is amenable to multiple protocols covering nitrocellulose and plate-based methods. Results are highly reproducible across technical and biological replicates, and there are no observed “batch effects” which are common for most multiplex molecular assays. Tests from basal and perturbed cancer cell lines indicate that this platform is comparable to orthogonal proteomic assays such as Reverse-Phase Protein Array, and applicable to measuring the pharmacodynamic effects of clinically-relevant cancer therapeutics. Furthermore, we demonstrate the potential clinical utility of the platform with protein profiling from breast cancer patient samples to identify molecular subtypes. Together, these findings highlight the potential of this platform for enhancing our understanding of cancer biology in a clinical translation setting.

AB - Molecular analysis of tumors forms the basis for personalized cancer medicine and increasingly guides patient selection for targeted therapy. Future opportunities for personalized medicine are highlighted by the measurement of protein expression levels via immunohistochemistry, protein arrays, and other approaches; however, sample type, sample quantity, batch effects, and “time to result” are limiting factors for clinical application. Here, we present a development pipeline for a novel multiplexed DNA-labeled antibody platform which digitally quantifies protein expression from lysate samples. We implemented a rigorous validation process for each antibody and show that the platform is amenable to multiple protocols covering nitrocellulose and plate-based methods. Results are highly reproducible across technical and biological replicates, and there are no observed “batch effects” which are common for most multiplex molecular assays. Tests from basal and perturbed cancer cell lines indicate that this platform is comparable to orthogonal proteomic assays such as Reverse-Phase Protein Array, and applicable to measuring the pharmacodynamic effects of clinically-relevant cancer therapeutics. Furthermore, we demonstrate the potential clinical utility of the platform with protein profiling from breast cancer patient samples to identify molecular subtypes. Together, these findings highlight the potential of this platform for enhancing our understanding of cancer biology in a clinical translation setting.

UR - http://www.scopus.com/inward/record.url?scp=85048206321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048206321&partnerID=8YFLogxK

U2 - 10.1074/mcp.RA117.000291

DO - 10.1074/mcp.RA117.000291

M3 - Article

C2 - 29531020

AN - SCOPUS:85048206321

VL - 17

SP - 1245

EP - 1258

JO - Molecular and Cellular Proteomics

JF - Molecular and Cellular Proteomics

SN - 1535-9476

IS - 6

ER -